Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin for Relapsed/Refractory Mantle Cell Lymphoma
NCT00038623Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2002
- Primary completion
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2002; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00038623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038623.